Home » Thought Leadership

Thought Leadership

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 119 posts
ISPOR Asia-Pacific 2020 research poster from CBPartners
September 7, 2020 | Research posters

ISPOR Asia-Pacific 2020: China’s 2019 NRDL Update – Implications on Global & Local Manufacturer Strategy

A research poster to evaluate 2019 NRDL negotiation outcomes as indicators of potential strategic approaches for multinational and domestic manufacturers to achieve NRDL listing.

Decorative image of blog post depicting biopharma
August 25, 2020 | Blogs

Ten Long-term Impacts of COVID-19 on Biopharma

COVID-19 has presented an abundance of short-term implications and challenges for biopharma companies; however, it is useful to understand and prepare for the longer-term impacts as the acute disruptions to regulatory processes and healthcare delivery begin to subside. To proactively prepare for a post-COVID-19 world, biopharma leaders should develop strategies to integrate technology across the value chain and increase focus on patient centricity in terms of process flows and treatment administration.

The 10 long term impacts of COVID-19 on biopharma from CBPartners
August 25, 2020 | Infographics

10 Long-term Impacts of COVID-19 on Biopharma

CBPartners lists the top 10 long-term trends and implications of COVID-19 on the biopharma industry as biopharma leaders prepare for a post-COVID-19 world.

August 5, 2020 | Blogs

Misconceptions of the 340B Drug Discount Program

Since its inception over 30 years ago, the 340B drug pricing program policy has evolved allowing for unprecedented expansion and influence. With this it has also become highly contested, especially in recent years as more legislation has been put forward to close 340B loopholes.